NASDAQ: SRZNSurrozen Inc Stock
$8.61-0.36 (-4.01%)
Updated Apr 25, 2024
SRZN Price
$8.61
Fair Value Price
$16.19
Market Cap
$27.54M
52 Week Low
$4.50
52 Week High
$16.19
P/E
-0.4x
P/B
0.73x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$43.04M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.22
Operating Cash Flow
-$40M
Beta
0.65
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SRZN Overview
Surrozen Incorporated is a biotechnology company that is developing tissue-specific antibodies to treat diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company's products in pipeline include SZN-043, a tissue-specific R-spondin mimetic for the treatment of severe liver disease, and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen was founded in 2015 and is headquartered in South San Francisco, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SRZN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SRZN ($8.61) is undervalued by 46.81% relative to our estimate of its Fair Value price of $16.19 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SRZN ($8.61) is significantly undervalued by 46.81% relative to our estimate of its Fair Value price of $16.19 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SRZN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SRZN due diligence checks available for Premium users.
Be the first to know about important SRZN news, forecast changes, insider trades & much more!
SRZN News
Valuation
SRZN fair value
Fair Value of SRZN stock based on Discounted Cash Flow (DCF)
Price
$8.61
Fair Value
$16.19
Undervalued by
46.81%
SRZN ($8.61) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SRZN ($8.61) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SRZN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SRZN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.4x
Industry
15.41x
Market
40.97x
SRZN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.73x
Industry
5.8x
SRZN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SRZN's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.9M
Profit Margin
0%
SRZN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$46.1M
Liabilities
$8.1M
Debt to equity
0.22
SRZN's short-term assets ($41.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SRZN's short-term assets ($41.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SRZN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.3M
Investing
$9.5M
Financing
$141.0k
SRZN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SRZN vs Biotech Stocks
Surrozen Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.